PET scan and EBV test guided treatment for nasal NK/T cell lymphoma
Part of Cancer clinical trials.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with a type of nasal lymphoma called extranodal NK/T cell lymphoma
- You are 18 years or older
- Your cancer is in an early stage (Ann Arbor stage I or II)
- You have not received any prior treatment for lymphoma
- You are generally in good health with adequate organ function (heart, liver, kidneys, blood counts)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for early-stage NK/T-cell lymphoma of the nose or throat. The treatment is adjusted based on how well the disease responds, aiming to be more effective and reduce side effects.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
This trial tests a new combination of drugs (chidamide, an anti-PD-1 antibody, and pegaspargase) against a standard treatment for people with advanced-stage, newly diagnosed NK/T-cell lymphoma. It aims to see if the new combination works better and is safe.
This study tests whether patients with a specific type of blood cancer (NK/T-cell lymphoma) in the nose or sinuses who have responded well to chemotherapy can be safely treated with reduced radiation doses instead of standard high-dose radiation. The goal is to reduce side effects while maintaining effective treatment.
This early-phase study tests personalized immune cells (EBV CAR-T or TCR-T) to treat nasopharyngeal cancer that has returned or spread. It aims to help the immune system find and attack the cancer after other treatments have not worked.
Hear when a new NK-T-Cell Lymphoma, Extranodal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.